254 results on '"Yajima, Toshitaka"'
Search Results
2. Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
3. Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients
4. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER
5. Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database
6. Treatment patterns and trajectories in patients after acute heart failure hospitalization
7. Impact of treatment of hyperkalaemia on quality of life: design of a prospective observational cohort study of long-term management of hyperkalaemia in patients with chronic kidney disease or chronic heart failure in Japan
8. Abstract 11780: Machine Learning Models to Predict Development of CKD and/or HF in Early Stages of Type 2 Diabetes Patients
9. Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study
10. Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan
11. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
12. Treatment patterns and trajectories in patients after acute heart failure hospitalization.
13. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose–response, phase 2/3 study
14. Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy
15. Prion-Induced Amyloid Heart Disease with High Blood Infectivity in Transgenic Mice
16. Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study
17. Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
18. Association of Hyperkalemia and Hypokalemia with Patient Characteristics and Clinical Outcomes in Japanese Hemodialysis (HD) Patients
19. Abstract 13365: Risk-benefit Evaluation in Cessation of Renin-angiotensin-aldosterone Inhibitors in Hyperkalemic Heart Failure Patients: A Japanese Real-world Study From Nationwide Administrative Database
20. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
21. Andexanet alfa (ONDEXXYA® for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence
22. Validation of a new instrument for measuring disease-specific quality of life: A pilot study among patients with chronic kidney disease and hyperkalemia
23. Additional file 6 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
24. Additional file 4 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
25. Additional file 2 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
26. Additional file 3 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
27. Additional file 5 of Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia
28. Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia
29. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
30. Changes in Treatment Satisfaction Over 3 Years in Patients With Type 2 Diabetes After Initiating Second-line Treatment
31. 873-P: Machine-Learning Models to Predict CKD and HF in Type 2 Diabetes Patients
32. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega‐3‐Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single‐Blind, Randomized, Placebo‐Controlled Trial
33. Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease.
34. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
35. Health Care Cost Analysis of PPI or P-CAB-First Treatment in Patients With Gastroesophageal Reflux Disease
36. Mita et al_supplementary data_Figshare.docx
37. β1 Integrin Gene Excision in the Adult Murine Cardiac Myocyte Causes Defective Mechanical and Signaling Responses
38. Abstract 9315: Mortality Risk Associated With Cessation of Mineralocorticoid Receptor Antagonists in Heart Failure Patients and Hyperkalemia; A Real-World Study From a Nationwide Administrative Database
39. Current trends in diabetes mellitus database research in Japan
40. Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
41. Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes
42. An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice
43. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart
44. Antiviral and myocyte protective effects of murine interferon-[beta] and -[[alpha].sub.2] in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice
45. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
46. Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
47. β-Blocker Therapy Combined with Low-Dose Pimobendan in Patients with Idiopathic Dilated Cardiomyopathy and Chronic Obstructive Pulmonary Disease: Report on Two Cases
48. Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection
49. Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
50. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.